When was Elastrin founded?

Elastrin was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Elastrin located?

Elastrin is headquartered in Simpsonville, United States. It is registered at 2 THE OLD ESTATE YARD HIGH STREET,EAST HENDRED,WANTAGE,OXFORDSHIRE,ENGLAND,OX12 8JY.

Who is the current CEO of Elastrin?

Matthias Breugelmans of Elastrin.

How many employees does Elastrin have?

As of Jun 30, 2026, the latest employee count at Elastrin is 5.

Is Elastrin a funded company?

Elastrin is a funded company, having raised a total of $17.2M across 7 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 16, 2018.

When was the latest funding round of Elastrin?

Elastrin's latest funding was a $***** Series A round on Sep 11, 2024, with participation from 0 investor.

Where does Elastrin rank among its competitors?

Elastrin ranks 73rd amongst 363 active competitors, of which 108 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Vor Biopharma, which secured $150M in Dec, 2025.

Who are the top competitors of Elastrin?

Elastrin's top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Vor Biopharma secured the most recent funding round in December, 2025.

Elastrin - 2026 Company Profile, Team, Funding, Competitors & Financials

Elastrin is a series A company based in Simpsonville (United States), founded in 2017 by Mirko Stange, Douglas Mulhall, Charles D Rice and Naren Vyavahare. It operates as a Developer of therapeutic targets related to arterial and lung diseases. Elastrin has raised $17.2M in funding from Kizoo. The company has 363 active competitors, including 108 funded and 102 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.

Company Details

Developer of therapeutic targets related to arterial and lung diseases. The company has built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that thickens the arteries and manages drugs' targets.

Website: www.elastrin.com/
Social
Email ID: *****@calcify.com
Registered Address: 2 THE OLD ESTATE YARD HIGH STREET,EAST HENDRED,WANTAGE,OXFORDSHIRE,ENGLAND,OX12 8JY

Key Metrics

Founded Year

2017

Location

Simpsonville, United States

Stage

Series A

Total Funding

$17.2M in 7 rounds

Latest Funding Round

Series A, Sep 11, 2024, $*****

Investors

Kizoo & 3 more

Ranked

73^rd among 363 active competitors

Employee Count

5 as on Jun 30, 2026

Similar Companies

Tenaya Therapeutics & 346 more

View Elastrin's full profile

Elastrin is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Elastrin Therapeutics, Inc. CIN: 824884018 , United States, Active		-	-	-
ELASTRIN THERAPEUTICS LIMITED CIN: 14203760 , United Kingdom, Active	Jun 28, 2022	-	1 (As on Dec 31, 2024)

Elastrin has raised a total funding of $17.2M over 7 rounds. Its first funding round was on Nov 16, 2018. Elastrin has 4 institutional investors.

Here is the list of recent funding rounds of Elastrin:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 11, 2024	2074258	Series A	8702066	7024102	9350983	2192527
Oct 25, 2023	2378135	Series A	8646230	9534489	5581598	4405879
Aug 18, 2023	5351067	Series A	8204015	8796380	8908481	2561649

Access funding benchmarks and valuations. Sign up today!

View details of Elastrin's funding rounds and investors

The founders of Elastrin are Mirko Stange, Douglas Mulhall, Charles D Rice and Naren Vyavahare.

Here are the details of Elastrin's key team members:

Mirko Stange: Co-Founder of Elastrin and founder of 4 other companies, including Ventac Partners, SilverSky LifeSciences and lino Biotech.
Douglas Mulhall: Co-Founder of Elastrin and founder of 1 other company.
Contact Info: 1 email address
Charles D Rice: Co-Founder of Elastrin.
Naren Vyavahare: Co-Founder & CSO of Elastrin.
Contact Info: 1 email address
Matthias Breugelmans: CEO of Elastrin.
Contact Info: 1 email address

View details of Elastrin's Founder profiles and Board Members

Elastrin's employee count trend

Elastrin has 5 employees as of Jun 26. Here is Elastrin's employee count trend over the years:

Uncover Elastrin's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elastrin include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Elastrin, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Fidelity Investments, RA Capital Management ... & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	66/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Aisling Capital & 16 others	66/100
7th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Humboldt Fund & 7 others	65/100
8th	Edgewise Therapeutics 2017, Boulder (United States), Public	Developer of therapeutics for skeletal and cardiac muscle diseases	$145M	Viking Global Investors, Novo Holdings & 12 others	64/100
9th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Quaker Partners Management, Athyrium Capital Management ... & 4 others	64/100
10th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
73rd	Elastrin 2017, Simpsonville (United States), Series A	Developer of therapeutic targets related to arterial and lung diseases	$17.2M	Kizoo, SCRA & 2 others	46/100